Ligand Pharmaceuticals | LGND - Ebit

Aktienkurs
204.92
Täglich Wechseln
-0.72 -0.35%
Monatlich
-7.38%
Jährlich
96.53%
Q2 Prognose
199.33




Ebit Veränderung Datum
Agenus USD 14.4M 19.26M 2025-12
Amgen USD 3.96B 464M 2025-12
Anika Therapeutics USD 646K 3.88M 2025-12
Arrowhead Research USD 40.81M 17.01M 2025-12
Baxter International USD -214.2M 415.4M 2025-12
Bristol-Myers Squibb USD 3.47B 567M 2025-12
Eli Lilly USD 8.99B 1.57B 2025-12
Enanta Pharmaceuticals USD -23.54M 6.31M 2024-12
Enviri Corporation USD -35.28M 61.58M 2025-12
Gilead Sciences USD 2.96B 551M 2025-12
GlaxoSmithKline GBP 1.44B 1.35B 2025-12
Glaxosmithkline GBP 2.3B 1.46B 2025-12
Heron Therapeutics USD 38K 3.83M 2025-12
Insmed USD -249.71M 11.64M 2025-12
Intrexon USD -26.3M 2.91M 2024-06
Ionis Pharmaceuticals USD -215M 54.82M 2025-12
Karyopharm Therapeutics USD -17.84M 8.44M 2025-12
Ligand Pharmaceuticals USD 158.89M 115.32M 2025-09
MacroGenics USD -12.1M 32.26M 2025-12
Merck USD 6.24B 1.32B 2025-12
Pacira USD 3.19M 9.96M 2025-12
Pfizer USD 4.65B 71M 2025-12
Rigel Pharmaceuticals USD 447K 1.52M 2024-06
Veracyte USD 24.63M 1.52M 2025-12